Clinical Trial Update: Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating PET imaging with an [18F]-labeled Substance P antagonist receptor quantifier to detect disease in patients with pancreatic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• [18F]-labeled Substance P antagonist receptor quantifier (18F-labeled Substance P antagonist receptor quantifier)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED